Skip Navigation

Skip Navigation

Issue No. 12  | March 23, 2012
View HTML version

AIDSinfo.nih.gov is pleased to provide you with a weekly update of highlights about what has happened in the world of HIV/AIDS treatment, prevention, and research. We hope you find this encapsulated view of HIV/AIDS news useful.

Globe of the earth

CDC Updates “Epidemiology of HIV Infection” Slide Set

The Centers for Disease Control and Prevention (CDC) recently updated the “Epidemiology of HIV Infection (through 2010)” slide set. The slide set provides statistical information on diagnoses of HIV infection and AIDS in the United States and dependent areas, including breakdowns of diagnoses by sex, transmission category, race/ethnicity, and year of diagnosis.


Study Examines Renal Function in People Infected with HIV Who Are Starting Therapy with Tenofovir and Either Efavirenz, Lopinavir, or Atazanavir

“Tenofovir is associated with reduced renal function, but it is not clear whether there is a greater decline in renal function when tenofovir is co-administered with a boosted protease inhibitor rather than with a nonnucleoside reverse transcriptase inhibitor (NNRTI). …

“We calculated the estimated glomerular filtration rate (eGFR) for patients in the Swiss HIV Cohort Study. We estimated the difference in eGFR over time between first therapies containing tenofovir and either the NNRTI efavirenz or the protease inhibitors lopinavir (LPV/r) or atazanavir (ATV/r), both boosted with ritonavir. …

“Patients on a first therapy of tenofovir co-administered with efavirenz (n=484), LPV/r (n=269) and ATV/r (n=187) were followed for a median of 1.7, 1.2 and 1.3 years, respectively. Relative to tenofovir and efavirenz, the estimated difference in eGFR for tenofovir and LPV/r was -2.6ml/min per 1.73m [95% confidence interval (CI) -7.3 to 2.2) during the first 6 months of therapy, then followed by a difference of 0.0ml/min per 1.73m (95% CI -1.1 to 1.1) for each additional 6 months of therapy. Relative to tenofovir and efavirenz, the estimated difference in eGFR for tenofovir and ATV/r was -7.6ml/min per 1.73m (95% CI -11.8 to -3.4) during the first 6 months of therapy, then followed by a difference of -0.5ml/min per 1.73m (95% CI -1.6 to 0.7) for each additional 6 months of therapy. …

“Tenofovir with either boosted protease inhibitor leads to a greater initial decline in eGFR than tenofovir with efavirenz; this decline may be worse with ATV/r than with LPV/r.”

More information is available:


Twitter - Stay connected FaceBook - Stay connected
ClinicalTrials.gov Info

Subscribe Info

Contact AIDSinfo
Download Adobe Acrobat(R) Reader TM to view PDF files located on this site.
ISSN 1558-3228